Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 3/20 | 0.85 |
| ▸ | ADORA1 known ✓ | P30542 | 3/20 | 0.85 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.85 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.85 |
| ▸ | DPP4 | P27487 | 1/20 | 0.85 |
| ▸ | MEN1 | O00255 | 1/20 | 0.85 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.85 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.85 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.85 |
| ▸ | GAPDH | P04406 | 1/20 | 0.85 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.85 |
| ▸ | STAT6 | P42226 | 1/20 | 0.85 |
| ▸ | PI4KA | P42356 | 1/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.85 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.85 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.85 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.85 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.85 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine SCHEMBL23093553 | 0.98 | ADORA3 (0.85) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL5600395 | 0.98 | ADORA3 (0.85) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL353215 | 0.97 | ADORA1 (0.83) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL662450 | 0.97 | ADORA1 (0.83) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL30414076 | 0.95 | ADORA1 (0.80) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL2357437 | 0.95 | ADORA1 (0.80) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL11632994 | 0.95 | ADORA1 (0.80) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL28583342 | 0.95 | ADORA1 (0.83) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL2248157 | 0.94 | ADORA1 (0.78) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL19511704 | 0.94 | ADORA1 (0.78) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 717 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116133639-A | Formulations and methods for treating inflammatory diseases | 维奥梅治疗公司 | 2023-05-16 | — | — | CN | claimed |
| US-20230144779-A1 | FORMULATIONS AND METHOD FOR TREATMENT OF INFLAMMATORY DISEASES | VYOME THERAPEUTICS INC. (US) | 2023-05-11 | — | — | US | claimed |
| CN-109265696-B | Preparation method of ceramic water reducing agent | 佛山一宇卫士陶瓷材料有限公司 | 2021-08-20 | — | — | CN | claimed |
| WO-2021124301-A1 | FORMULATIONS AND METHOD FOR TREATMENT OF INFLAMMATORY DISEASES | VYOME THERAPEUTICS INC. (US) | 2021-06-24 | — | — | WO | claimed |
| CN-102245643-A | Cosmetic composition containing acetylated oligoglucuronans | SEDERMA SA | 2011-11-16 | — | — | CN | claimed |
| EP-2367852-A1 | COSMETIC COMPOSITION CONTAINING ACETYLATED OLIGOGLUCURONANS | Sederma (FR) | 2011-09-28 | — | — | EP | claimed |
| WO-2010067327-A1 | COSMETIC COMPOSITION CONTAINING ACETYLATED OLIGOGLUCURONANS | SEDERMA (FR) | 2010-06-17 | — | — | WO | claimed |
| EP-4149415-B1 | SHAMPOO COMPOSITION COMPRISING ALKYL GLUCOSIDE | PROCTER & GAMBLE (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12605316-B2 | Alkenone-based formulations for topical applications | WOODS HOLE OCEANOGRAPHIC INSTITUTION (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4337333-B1 | SHAMPOO COMPOSITION | PROCTER & GAMBLE (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2026047750-A1 | ODOR REMOVAL FORMULATIONS AND SUBSTRATES COMPRISING THE SAME | KRID LABS LLP (IN) | 2026-03-05 | — | — | WO | disclosed |
| EP-4149416-B1 | SHAMPOO COMPOSITION COMPRISING DECYL GLUCOSIDE AND A CATIONIC GUAR | PROCTER & GAMBLE (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250387314-A1 | USE OF CELL MEMBRANE-BOUND SIGNALING FACTORS | AIVITA BIOMEDICAL INC (US) | 2025-12-25 | — | — | US | disclosed |
| WO-2000006089-A1 | HAIR CONDITIONING COMPOSITION COMPRISING CARBOXYLIC ACID/CARBOXYLATE COPOLYMER, AND VISIBLE PARTICLE | THE PROCTER & GAMBLE COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0972508-A1 | EXTRACELLULAR MATRIX PRODUCTION PROMOTER | SHISEIDO COMPANY LIMITED (JP) | 2000-01-19 | — | — | EP | disclosed |
| EP-0955035-A1 | Body odor preventing composition | SHISEIDO COMPANY LIMITED (JP) | 1999-11-10 | — | — | EP | disclosed |
| US-5827920-A | STABLE SURFACTANT-FREE AQUEOUS MIXTURES OF ACRYLIC ACID-METHACRYLIC ACID COPOLYMERS, SOLID HIGHER ALCOHOLS, SILICONE OILS, FOR COSMETICS HAVING GOOD ORGANOLEPTIC PROPERTIES | SHISEIDO COMPANY, LTD. (JP) | 1998-10-27 | — | — | US | disclosed |
| EP-0852949-A2 | Use of alpha-amino-acids for enhancing desmosomal degradation or stratum corneum desquamation | SHISEIDO COMPANY LIMITED (JP) | 1998-07-15 | — | — | EP | disclosed |
| EP-0815838-A2 | External skin treatment composition | SHISEIDO COMPANY, LTD. (JP) | 1998-01-07 | — | — | EP | disclosed |
| EP-0779097-A1 | EMULSION COMPOSITION | SHISEIDO COMPANY LIMITED (JP) | 1997-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605316-B2 | Alkenone-based formulations for topical applications | CUTA, FLNA, TELO2 | ADORA3 936/4885ADORA1 742/4885ADORA2A 1990/4885 |
| US-20250387314-A1 | USE OF CELL MEMBRANE-BOUND SIGNALING FACTORS | SHH, JUP, CTNND1 | ADORA3 2166/4885ADORA1 1817/4885ADORA2A 1462/4885 |
| US-20230144779-A1 | FORMULATIONS AND METHOD FOR TREATMENT OF INFLAMMATORY DISEASES | UACA, TNF, TPMT | ADORA3 3174/4885ADORA1 1287/4885ADORA2A 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.